

Biomimetic Synthesis of Magnetosomes for Biomedical Application

Jennifer Bain, Sarah Staniland

Department of Chemistry, University of Sheffield
Brook Hill, Sheffield, UK
jbain@sheffield.ac.uk; s.s.staniland@sheffield.ac.uk

Extended Abstract

Micro/nano- vesicles (solution encapsulated liposomes or polymersomes) are currently utilised in many applications and potential applications, such as delivery of drugs in medicine.(Abra, Bankert et al. 2002, Ren, Liu et al. 2012) In medicine, vesicles are used to encapsulate drugs, and release them at specific locations in response to a specific stimuli by engineering of the vesicle membrane.(Ganta, Devalapally et al. 2008) This means that lower doses of drugs are required significantly improving the treatment efficiency whilst reducing the magnitude and severity of any side effects. Currently, medical researchers are developing therapies which can simultaneously diagnose and treat a wide range of diseases, termed theranostic agents.(Santhosh and Ulrich 2013, Svenson 2013) Our research, is focussed on the development of magnetic vesicles for use as theranostic agents. We are combining the diagnostic capability of magnetic nanoparticles (MNPs), currently used in MRI scanning with their therapeutic capability as seen in magnetic hyperthermia to treat tumours.(Pankhurst, Connolly et al. 2003, Pankhurst, Thanh et al. 2009) Biocompatibility is achieved by precipitation within vesicle, currently used as drug delivery agents.

Magnetospirillum magneticum AMB-1 synthesise magnetosomes, which are internally formed vesicles containing a single biomineralised MNP. The magnetosome lipid membrane supports an array of magnetic bacteria specific proteins that allow the formation of uniformly sized and shaped magnetosome MNPs.(Tanaka, Mazuyama et al. 2011) To be suitable for medical use, both vesicles and MNPs must be of a consistent size and shape, to ensure consistent properties and predictable behaviour during application. The formation of our proposed theranostic agent takes inspiration from magnetic bacteria to create artificial magnetosome-like theranostic magnetic nanovesicles *in situ* under mild reaction conditions, which has been successfully achieved. MNPs in our system are precipitated within the vesicle membrane, and appear responsive in initial MRI and hyperthermia testing. The benefit of MNP precipitation within the vesicle membrane is that the core is free for encapsulation of hydrophilic drugs for delivery controlled by application of a magnetic field. Work is now focussed on the incorporation of biomineralisation and membrane iron-transport proteins from the magnetic bacteria into our vesicles to further control the MNPs size and shapes within the nanovesicles and thus tune the magnetic properties.

References

- Abra, R., R. Bankert, F. Chen, N. Egilmez, K. Huang, R. Saville, J. Slater, M. Sugano and S. Yokota (2002). "The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients." *Journal of liposome research* **12**(1-2): 1-3.
- Ganta, S., H. Devalapally, A. Shahiwala and M. Amiji (2008). "A review of stimuli-responsive nanocarriers for drug and gene delivery." *Journal of controlled release* **126**(3): 187-204.
- Pankhurst, Q., N. Thanh, S. Jones and J. Dobson (2009). "Progress in applications of magnetic nanoparticles in biomedicine." *Journal of Physics D: Applied Physics* **42**(22): 224001. XXX-2

- Pankhurst, Q. A., J. Connolly, S. K. Jones and J. Dobson (2003). "Applications of magnetic nanoparticles in biomedicine." *Journal of Physics D-Applied Physics* **36**(13): R167-R181.
- Ren, T., Q. Liu, H. Lu, H. Liu, X. Zhang and J. Du (2012). "Multifunctional polymer vesicles for ultrasensitive magnetic resonance imaging and drug delivery." *Journal of Materials Chemistry* **22**(24): 12329-12338.
- Santhosh, P. B. and N. P. Ulrih (2013). "Multifunctional Superparamagnetic Iron Oxide Nanoparticles: Promising Tools in Cancer Theranostics." *Cancer letters*.
- Svenson, S. (2013). "Theranostics: Are We There Yet?" *Molecular pharmaceuticals*.
- Tanaka, M., E. Mazuyama, A. Arakaki and T. Matsunaga (2011). "Mms6 protein regulates crystal morphology during nano-sized magnetite biomineralization in vivo." *Journal of Biological Chemistry* **286**(8): 6386-6392.